Table 3 Response criteria: LSM difference between canakinumab and placebo for HAQ and FACIT-F scores at week 12
Variable | Canakinumab 150 mg SC q4wk, n = 69 | Canakinumab 300 mg SC q2wk, n = 64 | Canakinumab 300 mg SC q2wk + 600 mg IV loading dose, n = 71 |
|---|---|---|---|
HAQ score | |||
Baseline, mean (SD) | 1.643 (0.6106) | 1.572 (0.6106) | 1.613 (0.4879) |
Difference vs. placebo in LS mean change (95% CI) | -0.2 (-0.3, 0.0) | -0.1 (-0.3, 0.1) | -0.1 (-0.3, 0.0) |
p-value | 0.036* | 0.253 | 0.171 |
FACIT-F score | |||
Baseline, mean (SD) | 25.6 (12.51) | 25.8 (11.87) | 22.5 (9.26) |
Difference vs. placebo in LS mean change (95% CI) | 4.4 (1.3, 7.5) | 2.5 (-0.7, 5.6) | 3.5 (0.4, 6.7) |
p-value | 0.006* | 0.120 | 0.028* |